Bronson Soothe Pain Relief

Capsaicin


Bronson Nutritionals, Llc
Human Otc Drug
NDC 83158-387
Bronson Soothe Pain Relief also known as Capsaicin is a human otc drug labeled by 'Bronson Nutritionals, Llc'. National Drug Code (NDC) number for Bronson Soothe Pain Relief is 83158-387. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Bronson Soothe Pain Relief drug includes Capsaicin - .25 mg/mL . The currest status of Bronson Soothe Pain Relief drug is Active.

Drug Information:

Drug NDC: 83158-387
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Bronson Soothe Pain Relief
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Capsaicin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Bronson Nutritionals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAPSAICIN - .25 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 26 Dec, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:BRONSON NUTRITIONALS, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:198555
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0716563614010
0716563614041
UPC stands for Universal Product Code.
UNII:S07O44R1ZM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
83158-387-0259 mL in 1 TUBE (83158-387-02)26 Dec, 2022N/ANo
83158-387-04118 mL in 1 TUBE (83158-387-04)26 Dec, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic

Product Elements:

Bronson soothe pain relief capsaicin aloe vera leaf water arnica montana flower ascorbyl palmitate c13-14 isoparaffin cetyl alcohol chamomile diazolidinyl urea emu oil witch hazel isopropyl alcohol isopropyl myristate lamium album whole laureth-7 menthol methylparaben dimethyl sulfone polyethylene glycol 400 propylparaben propylene glycol sorbitol .alpha.-tocopherol acetate capsaicin capsaicin

Indications and Usage:

Uses: for temporary relief of minor aches and pains of the muscles and joints associted with simple backache, arthritis, strains, bruises and sprains.

Warnings:

Warnings for external use only. avoid contact with eyes. do not apply to open wounds or damaged skin. if symtoms persist for more than seven days, discontinue use and consult physician. keep out of reach of children. if swallowed, contact physician. do not bandage tightly . if pregnant or breast feeding, contact physician prior to use.

Dosage and Administration:

Directions: apply directly to affected area. do not use more than four times per day.

Package Label Principal Display Panel:

Package labeling:59ml label59ml

Package labeling:118ml label118ml


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.